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Pharmacokinetic and tissue penetration studies of grepafloxacin, a new broad-spectrum fluoroquinolone, show that it 
has useful properties for the treatment of respiratory tract infections. Grepafloxacin has a volume of distribution that is 
larger than those of many of the other fluoroquinolones and is concentrated in alveolar macrophages, bronchial mucosa 
and epithelial lining fluid to a greater extent than are certain other fluoroquinolones. Grepafloxacin concentrations 
achieved in plasma after a 400-mg oral dose are well in excess of those required to inhibit the respiratory pathogens 
Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis. Streptococcus pneumoniae is also covered 
for most of the dosing interval, but at normal dose levels grepafloxacin might not inhibit fnterococcus faecalis. The 
maximum plasma concentrations and area under the concentration-time curve achieved with grepafloxacin suggest 
that it will be effective for the treatment of community-acquired pneumonia and acute exacerbations of chronic 
bronchitis. The pharmacokinetics of fluoroquinolones are among their most useful properties. The aim of this paper is 
to demonstrate whether the differences between grepafloxacin and the other fluoroquinolones are of therapeutic 
significance. 
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STRUCTURE-ACTIVITY RELATIONSHIP 
One of the main structural differences between grepa- 
floxacin and other fluoroquinolones is the presence of 
the two amine groupings, a secondary and a tertiary 
amine, at position 7. Although difficult to prove, it is 
possible that the degree of amination of the molecule 
at this site may be related to some important pharma- 
cokinetic properties. Although all fluoroquinolones 
have large volumes of distribution, fluoroquinolones 
with the structure described above tend to have larger 
volumes of distribution than the others [l]. 
A volume of distribution of 1 L/kg is equivalent to 
the body volume being penetrated by the drug. A drug 
with a volume of distribution of 2 L/kg or more is 
being concentrated somewhere in the body. In general, 
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the fluoroquinolones concentrate at two important 
sites: within the phagocytic cells of the body-the 
white blood cells and macrophages-and in the various 
mucosae of the body, often the site of infection. 
Thus, high volumes of distribution, leading to high 
tissue levels of drug, particularly in the phagocytes and 
mucosa, are important pharmacokinetic characteristics 
of the fluoroquinolones. 
PHARMACOKINETICS 
In an early study using grepafloxacin, s i x  healthy male 
volunteers (mean age 28 years, mean weight 73 kg) 
were given a single oral dose of grepafloxacin, 400 mg 
[2].  The levels of the drug were measured in plasma, in 
urine and in a cantharidin-induced inflammatory fluid 
model. The data were analyzed by a two-compartment 
(plasma) or one-compartment (inflammatory fluid) 
model. 
There is considerable biological variation in the 
inflammatory fluid data using this model. After oral 
administration, grepafloxacin was shown to penetrate 
rapidly into plasma and, somewhat later though still 
fairly rapidly, into the inflammatory fluid (Figure 1). 
Peak concentration was achieved at about 2 h in plasma 
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Figure 1 Concentration-time curves of grepafloxacin in 
plasma (0) and inflammatory fluid (A) in six healthy 
volunteers. Reproduced with kind permission &om the 
American Society for Microbiology, from Child et a1 [2]. 
and at about 5 h in inflammatory fluid (Table 1). After 
5-6 h, the level of drug in the inflammatory fluid was 
higher than that in the plasma. 
The terminal half-life of grepafloxacin is approxi- 
mately 12 h, and, even 12 h after a single dose, plasma 
levels are in excess of0.5 mg/L. Plasma levels at 24 h 
have been shown to be significant [3] .  
Grepafloxacin’s volume of distribution was 253 L, 
which conipares with 150 L for ciprofloxacin [4]. The 
percentage penetration of grepafloxacin into the 
inflammatory fluid was 180%, and this compares with 
110% for ciprofloxacin [4], 120% for sparfloxacin [S] 
and about 80% for ofloxacin [6]. Grepafloxacin pene- 
trates into the inflammatory fluid to a greater extent 
than any other fluoroquinolone we have studied. 
Other multidose pharmacokinetic studies have 
shown similar results, with grepafloxacin half-lives of 
about 12-1 5 h (Table 2) [3]. Doubling the dose doubles 
the area under the concentration-time curve (AUC). 
Minimum inhibitory concentrations 
An oral dose of grepafloxacin, 400 mg, achieves plasma 
concentrations that are well in excess of those required 
to inhibit (in an in vitro model) the respiratory 
pathogens Staphylococcus aureus, Haemoplzilus influenzae 
and Moraxella ratarrhalis [2,7]. Streptocorcus pneumoniae 
was also covered for most of the dosing interval, but 
at normal dose levels grepafloxacin may not inhibit 
Enterococcus faecalis infections. H .  i n j u e n z a e  and M.  
catarrhalis were covered for some 36 h after a single oral 
dose of grepafloxacin, 400 mg [2,7]. 
Esckerichia coli and Salmonella spp. are extremely 
sensitive, and grepafloxacin would be expected to be 
active against them [8] .  Grepafloxacin should not be 
used to treat infections with Pseudomonas aevuginosa or 
anaerobic organisms, such as Bacteroides spp. 
Metabolism 
In common with other fluoroquinolones, there is 
some nietabolisni of grepafloxacin with opening up 
of the ring structure at  position 5, and some 
glucuronidation, the product of which has minimal 
microbiological activity compared to the parent com- 
pound. Grepafloxacin is eliminated by metabolism 
Table 1 Pharmacokinetics of grepafloxacin, following a single 400-mg dose, in six healthy male volunteers. Results are 
means If- standard deviations. 
Volume of 
Tissue T,,,,3x (h) C,,, (mg/L) distribution (L) AUC: 0 .  Penetration (“A) 
Plasma 2.0 1.5f0 .3  253.2 +- 58.0 12 l f 2 . 4  - 
Inflammatory fluid 4.821.9 1.1 f 0 . 3  - 22.0f 12.9 180.hi114 
~~~ 
T,,,,, = time at which maximum drug concentration was achieved; GI,= maximum drug concentration; T I  )= elimination half-life; 
AUCo-m= area under the concentration-time curve from 0 h to infinity. Penetration=(AUCo-m for inflaimnatory fluid/AUCo-m fox 
plasma) x 100. Adapted from Child et al [2]. 
Table 2 Multidose pharmacokinetics of grepafloxacin, 400 nig and 800 mg, once daily, for 14 days 
1)ose (mg) ? ’ I ’ ~  (h) GI, (mg/L) C,,,,, (mg/L) AUCo 2 1 1 ~  Fraction excreted (“A) 
400 15.7 1.35 0.22 14.4 14.3 
800 14.0 2.74 0.57 34.0 13.0 
T I  ?= termnal elimination-phase half-life; C,,,=maximum observed plasma concentration; C,,,,,,=minimum observed plasma concentration; 
AUC+24h=area under the concentration-time curve from 0 h to infinity 
Adapted from Efthymiopoulos et a1 [3]. 
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Figure 2 Accumulation of quinolones in polymorphonuclear leukocytes. Based on Taira et al [lo]. 
primarily through the liver. Metabolites account for less concentrated 2-3-fold [13]. In alveolar macrophages, 
than 10% of the dose in plasma, urine and feces. grepafloxacin is concentrated over 100-fold [ll], 
Urinary excretion of unchanged drug ranges from 6% compared with about 50-fold for ciprofloxacin [4]. 
to 14% [9]. A total of 27% of drug is eliminated In comparison, if other classes of antimicrobial 
unchanged in the feces (data on file). agents are considered, p-lactam concentrations in 
TISSUE PENETRATION 
Respiratory tract penetration by fluoroquinolones can 
be assessed by measuring antibiotic concentration in 
the sputum by endotracheal suction, bronchial biopsy 
or bronchoalveolar lavage. Grepafloxacin is found to 
accumulate in the polymorphonuclear cells (Figure 2) ,  
where many pathogens can reside, and the concen- 
trations achieved are greater than those for ofloxacin, 
levofloxacin and DR-3354 [lo]. 
In epithelial lining fluid, there are very high 
concentrations that peak in excess of 10 mg/L (Table 
3, Figure 3) [11,12]. Here, grepafloxacin is concen- 
trated about 13-fold compared with ciprofloxacin, 
which concentrates 5-7-fold [4]. In bronchial mucosa, 
the mean levels exceed those in plasma by about 
three-fold [ 111. Other fluoroquinolones tend to be 
Figure 3 Penetration of tissues in the respiratory tract by 
grepafloxacin, 400 mg/day, for 4 days. Reproduced with 
permission from Cook et al [Ill. MIC value for 
Streptococcus pneumoniae taken &om Pankuch et al [12]. 
Table 3 Respiratory tract pharmacokmetics of grepafloxacin; n=24, mean timez4.5 h (range 0.42-12.8 h) 
Alveolar Bronchial Epithelial 
Plasma mucosa lining fluid macrophages 
Parameter mg/L mg/kg mg/L mg/L 
Mean 1.2 3.4 14 177 
Range 0.18-2.3 0.8-8.4 1.7-48.6 13.5-417 
Mean tissue/plasma ratio 3.1 12.3 181 
Kange 1.7-5.5 0.8-42 17-551 
(2 SD) (? 1 .O) (28.9) (2 145) 
Based on Cooke et al [ I l l .  
S 2 4  C l in ica l  M i c r o b i o l o g y  and  In fec t i on ,  Vo lume 4 Supp lemen t  1 
Table 4 Comparison of antimicrobial penetration of the 
respiratory tract with fluoroquinolones, p-lactams and 
macrolides 
Bronchial Epithelial Alveolar 
Drug class mucosa lining fluid macrophages 
Fluoroquinolones 1.5-3:l 3-12:l 10-34:l 
Macrolides 2-10:13 10+:1 20+:1a 
P-Lactams 0 4.1 0.25:1 0.1:l 
'Depends on time and the agent tested. Reproduced with kind 
permision from the BMJ Publishing Group, from Honeybourne 
[141. 
bronchial  mucosa only achieve abou t  40% of se rum 
levels (Table 4) [14]. Some macrolides, e.g. azithro- 
mycin,  penetrate t h e  bronchial mucosa well, whereas 
others,  such  as erythromycin,  do not .  In epithelial 
lining fluid, p-lactams only reach concentrations 25% 
those of serum, whereas some  macrolides penetrate 
well. Macrolides, but not p-lactams, penetrate alveolar 
macrophages [14]. 
CORRELATION OF PHARMACODYNAMICS AND 
OUTCOME 
The ratio of peak  concentration t o  MIC and  of AUC 
to MIC are considered impor tan t  for prediction of 
efficacy; wh ich  is used depends t o  some  exten t  on the  
disease be ing  treated. T h e  Schentag data suggest that  in 
nosocomial pneumonia  t h e  AUC/MIC ratio needed is 
about  125 : l  [15]. Th i s  is achieved for grepafloxacin. In 
community-acquired pneumonia ,  i n  w h i c h  it is n o t  
necessary t o  be quite so rigorous as in nosocomial 
pneumonia ,  e i ther  an  AUC/MIC ratio of 5O:l o r  a 
p e a k / M I C  ratio of 10 is considered reasonable [16]. 
Grepafloxacin would be expec ted  t o  be effective i n  
these two diseases, given tha t  doses of 400 or 600 
mg/day  are used; w i t h  a peak AUC of 19 .7  mg/L/h ,  
a grepafloxacin peak  s e r u m  level of about  1 .4  mg/L 
and  given a n  MIC of Streptococcus pneumoniae of about  
0.12 mg/L, the AUC/MIC ratio is about  150 a n d  the 
peak /MIC ratio is about  12. 
CONCLUSIONS 
T h e  fluoroquinolones are interesting agents from a 
pharmacokinetic viewpoint. They penetrate rapidly 
in to  the blood, pass rapidly into extracellular fluid 
and  inflammatory exudates, penetrate phagocytic cells 
(macrophages, white blood cells) and  the  mucosa and  
are concentrated in these sites a n d  stdl maintain good 
se rum levels relative t o  M I C s .  As might be expected, 
there  is less penetration i n t o  s o m e  of t h e  more 
specialized sites of t h e  body, such  as cerebrospinal 
fluid and  the  anterior eye. For the impor tan t  sites of 
common infections, such  as lower respiratory tract 
infections, however, t he  high concentrations achieved 
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